Browse by intervention

Ezetimibe: what it changed, and what it did not

One intervention, every measured benefit and result that did not improve. See who it moved for, where it stayed neutral or went the other way, and the next hypothesis Phoenix can validate.

Phoenix APOE4 Research · Reviewed by Kevin Tran, APOE4/4 carrier and founder · Data through 2026-08-23 · How to read this research

How to read this

Observational research: real APOE4 carriers tracked over time, each compared with their own earlier self. Members chose their interventions, with no randomisation or placebo group. Everything else they changed is shown beside each result.

Read the full methods and limits

Key findings

Phoenix has measured Ezetimibe against 5 exact outcomes for APOE4 carriers. Member #29E727 lowered ApoB from 131 to 90 mg/dL in 133 days on an ezetimibe-led combination. Member #6FAEFA's HDL cholesterol moved from 74 to 89 mg/dL in 70 days. Three members lowered LDL cholesterol in windows where ezetimibe was the most mechanistically established component of a larger combination. The same three members' total cholesterol fell alongside their LDL cholesterol. Member #B50FCD's Triglycerides moved from 59.4 to 46.9 mg/dL in 85 days.

Ezetimibe evidence by outcome
OutcomeDirectionWhat we observed
Apolipoprotein BRepeated positiveMember #29E727 lowered ApoB from 131 to 90 mg/dL in 133 days on an ezetimibe-led combination.
HDL cholesterolRepeated positiveMember #6FAEFA's HDL cholesterol moved from 74 to 89 mg/dL in 70 days.
LDL cholesterolRepeated positiveThree members lowered LDL cholesterol in windows where ezetimibe was the most mechanistically established component of a larger combination.
Total cholesterolRepeated positiveThe same three members' total cholesterol fell alongside their LDL cholesterol.
TriglyceridesPositive individual resultMember #B50FCD's Triglycerides moved from 59.4 to 46.9 mg/dL in 85 days.

Questions about Ezetimibe

What is the effect of Ezetimibe for APOE4 carriers?

Phoenix has measured Ezetimibe against 5 exact outcomes for APOE4 carriers. Member #29E727 lowered ApoB from 131 to 90 mg/dL in 133 days on an ezetimibe-led combination. Member #6FAEFA's HDL cholesterol moved from 74 to 89 mg/dL in 70 days. Three members lowered LDL cholesterol in windows where ezetimibe was the most mechanistically established component of a larger combination. The same three members' total cholesterol fell alongside their LDL cholesterol. Member #B50FCD's Triglycerides moved from 59.4 to 46.9 mg/dL in 85 days.

Does Ezetimibe change Apolipoprotein B for APOE4 carriers?

Member #29E727 lowered ApoB from 131 to 90 mg/dL in 133 days on an ezetimibe-led combination. Support: 2 logged members, 2 members with repeats, 2 observations, 4 measurements.

Does Ezetimibe change HDL cholesterol for APOE4 carriers?

Member #6FAEFA's HDL cholesterol moved from 74 to 89 mg/dL in 70 days. Support: 4 logged members, 4 members with repeats, 4 observations, 8 measurements.

Does Ezetimibe change LDL cholesterol for APOE4 carriers?

Three members lowered LDL cholesterol in windows where ezetimibe was the most mechanistically established component of a larger combination. Support: 4 logged members, 4 members with repeats, 4 observations, 8 measurements.

Does Ezetimibe change Total cholesterol for APOE4 carriers?

The same three members' total cholesterol fell alongside their LDL cholesterol. Support: 5 logged members, 5 members with repeats, 5 observations, 10 measurements.

Does Ezetimibe change Triglycerides for APOE4 carriers?

Member #B50FCD's Triglycerides moved from 59.4 to 46.9 mg/dL in 85 days. Support: 1 logged members, 1 members with repeats, 1 observations, 2 measurements.

What changed for real APOE4 carriers?

Search by health goal or intervention to see what changed for real members, including results that moved the wrong way.

Ezetimibe · 5 outcomes shown.

Intervention categoryMedications
InterventionEzetimibe

Ezetimibe

MedicationsOutcomes: 5

Apolipoprotein B: Decrease 36–41 mg/dL

Cases: 2Case range

HDL cholesterol: Increase 9–15 mg/dL

Cases: 4Case range

LDL cholesterol: Decrease 22–52 mg/dL

Cases: 4Case range

Total cholesterol: Decrease 14.9–79 mg/dL

Cases: 5Case range

Triglycerides: Decrease 12.5 mg/dL

Cases: 1

The Beat the Odds Study

The 43-page study: what members tried, how their bloodwork and wearable results changed, and what else changed alongside them.

Download the Beat the Odds Study

Turn evidence into your next test

I built this so nobody has to be the first to try something.

476 members have already tried, measured and logged. Join Phoenix and your next blood draw joins the same Navigator you are reading.

Join Phoenix